The 1st group of Australian patients received GI Dynamics‘ (ASX:GID) EndoBarrier obesity and Type II diabetes treatment device this week at the company’s newly established center in Melbourne.
The news sent GID shares up 6.7% to $1.11 as of about 3:30 p.m. today.